Inactive Instrument

Pediatrx Inc Stock OTC Bulletin Board

US70532X1072

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

25-02-18	Ignite Proteomics LLC acquired Proprietary Laboratory Analyses code 0249U from Theralink Technologies, Inc..	CI
24-05-06	IMAC Holdings, Inc. acquired Assets of Theralink Technologies, Inc.	CI

Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	615K 531K 498K 454K 853K 58.82M 865K 5.84M 2.29M 29.47M 2.31M 2.26M 98.02M	P/E 2022	-1.59x	P/E 2023	-0.18x
Enterprise Value	19.38M 16.73M 15.69M 14.3M 26.88M 1.85B 27.25M 184M 72.1M 928M 72.75M 71.18M 3.09B	EV / Sales 2022	44,915,754x	EV / Sales 2023	40,045,900x
Free-Float	17.39%	Yield 2022 *	-	Yield 2023	-

25-02-18	Ignite Proteomics LLC acquired Proprietary Laboratory Analyses code 0249U from Theralink Technologies, Inc..	CI
24-05-06	IMAC Holdings, Inc. acquired Assets of Theralink Technologies, Inc.	CI
24-05-05	Theralink Technologies, Inc. cancelled the acquisition of IMAC Holdings, Inc. in a reverse merger transaction.	CI
24-02-20	Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
24-01-05	Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI
24-01-04	Theralink Technologies, Inc. Auditor Raises 'Going Concern' Doubt	CI
23-11-03	Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute?s Molecular Tumor Board	CI
23-08-21	Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
23-07-25	IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors	CI
23-06-27	Theralink Technologies, Inc. Announces Chief Executive Officer Changes	CI
23-06-27	Theralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical Officer	CI
23-05-15	Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI
23-05-14	Theralink Technologies, Inc. entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. for $0.9 million in a reverse merger transaction.	CI

24-03-06	Theralink Technologies : Accelaration/Increase of Financial Obligation - Form 8-K	PU
23-12-18	Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates	AQ
23-11-13	Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4	AQ
23-11-03	Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board	AQ
23-10-05	Four Penny Stocks That Might Move On News (EPAZ, THER, SDNR, HNRC)	AQ

Manager	Title	Age	Since
Justin Davis CTO	Chief Tech/Sci/R&D Officer	-	2022-11-30
Michael Ruxin CEO	Chief Executive Officer	80	2017-12-31
Trevor McCartney SAM	Sales & Marketing	-	2019-02-28

Director	Title	Age	Since
Jeffrey Busch CHM	Chairman	68	2020-06-17
Michael Ruxin BRD	Director/Board Member	80	2020-06-17
Yvonne Fors BRD	Director/Board Member	54	2020-06-17

Pediatrx Inc Stock OTC Bulletin Board

Stocks

US70532X1072

Biotechnology & Medical Research

Valuation: Pediatrx Inc

Latest news : Pediatrx Inc

Press Releases: Pediatrx Inc

Managers and Directors: Pediatrx Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.80%	+7.80%	+70.64%	+114.21%	70.07B
ARGENX SE	+17.12%	+11.50%	+54.42%	+87.30%	52.87B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	+2.26%	+0.09%	+49.19%	+11.90%	23.61B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.38B
PHARMAESSENTIA CORPORATION	-6.00%	+6.02%	+244.39%	+430.80%	19.43B
GENMAB A/S	+3.80%	+5.62%	+40.50%	-15.26%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.38%	-1.14%	+20.39%	+567.31%	15.85B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.7B
Average	+2.95%	+0.14%	+55.25%	+201.15%	29.3B
Weighted average by Cap.	+5.10%	+2.25%	+56.29%	+168.78%

	2022	2023
Net sales	0.57 0.49 0.46 0.42 0.79 54.3 0.8 5.39 2.11 27.2 2.13 2.09 90.49	0.61 0.52 0.49 0.45 0.84 58.02 0.85 5.76 2.26 29.07 2.28 2.23 96.69
Net income	-12.74M -11M -10.32M -9.4M -17.67M -1.22B -17.92M -121M -47.41M -610M -47.84M -46.8M -2.03B	-30.91M -26.68M -25.03M -22.8M -42.87M -2.96B -43.47M -293M -115M -1.48B -116M -114M -4.92B
Net Debt	3.98M 3.43M 3.22M 2.93M 5.52M 380M 5.59M 37.76M 14.8M 191M 14.93M 14.61M 634M	18.76M 16.2M 15.2M 13.84M 26.03M 1.79B 26.39M 178M 69.81M 899M 70.45M 68.92M 2.99B